logo
logo

Congruence Therapeutics Inc. Announces Us$50 Million Series A Financing To Advance Platform Targeting Diseases Of Protein Misfolding

Congruence Therapeutics Inc. Announces Us$50 Million Series A Financing To Advance Platform Targeting Diseases Of Protein Misfolding

02/08/22, 8:00 AM
Money raised
$50 million
Round Type
series a
Congruence Therapeutics, a biotechnology company working at the interface of computational and experimental drug discovery to design novel small molecules for diseases of protein misfolding, announced today the closing of a US$50 million, tranched, series A financing. The financing was led by Amplitude Ventures and Fonds de solidariteĢ FTQ, with participation from Lumira Ventures, Investissement Quebec, OrbiMed Advisors, Driehaus Capital Management, and others.

Company Info

Company
Congruence Therapeutics
Additional Info
Congruence Therapeutics is a biotechnology company working at the interface of computational and experimental drug discovery to design novel small molecules for diseases of protein misfolding. Using structural bioinformatics, computational chemistry, and machine learning, the Company is deploying an in silico platform that enables the design of new pharmacological stabilizers, a validated class of small molecules, at an unprecedented speed and scale. For more information, please visit www.congruencetx.com.